Effect of halving the dose of venlafaxine to adjust for putative pharmacokinetic and pharmacodynamic changes in an animal model of chronic hepatic encephalopathy

Clinical Neuropharmacology

Volumn 24, Issue 6, 2001, Pages 324-333

  Wikell, Cecilia ^a,b,d   Kugelberg, Fredrik C ^b   Hjorth, Stephan ^c   Apelqvist, Gustav ^a   Bengtsson, Finn ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c Department of Pharmacology and Clinical Neuroscience ^*  (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Hepatic encephalopathy; Noradrenaline; Pharmacodynamic; Pharmacokinetic; Serotonin; Venlafaxine

Indexed keywords

NORADRENALIN; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HEPATIC ENCEPHALOPATHY; LIVER FUNCTION; MONOAMINERGIC SYSTEM; NEUROTRANSMITTER RELEASE; NONHUMAN; PHARMACODYNAMICS; PORTOCAVAL SHUNT; PRIORITY JOURNAL; RAT; SYNAPTIC TRANSMISSION;

ANIMALS; BIOTRANSFORMATION; BRAIN CHEMISTRY; CHRONIC DISEASE; CYCLOHEXANOLS; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HEPATIC ENCEPHALOPATHY; MALE; MICRODIALYSIS; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0035204034     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200111000-00003     Document Type: Article

References (33)

1. Hepatocerebral dysfunction and brain serotonin
2. Current theories on the pathogenesis of hepatic encephalopathy
3. Brain tryptophan/serotonin perturbations in metabolic encephalopathy and the hazards involved in the use of psychoactive drugs
4. Portocaval shunt in the rat
5. Animal models of hepatic encephalopathy and hyperammonemia
6. Portacaval shunt in the rat: Selective alterations in behavior and brain serotonin
7. The impact of time after portacaval shunt in the rat on behavior, brain serotonin, and brain and muscle histology
8. Gender and diurnal effect on specific open-field behavioral patterns in the portacaval shunted rat
9. Central versus peripheral spontaneous behavioral abnormalities in experimental hepatic encephalopathy
10. Diurnal and gender effects by chronic portacaval shunting in rats on spontaneous locomotor and rearing activities in an open-field
11. Neocortical dialysate monoamines of rats after acute, subacute, and chronic liver shunt
12. p-Chloroamphetamine and d-fenfluramine induced brain serotonin release in experimental portal systemic encephalopathy
13. Potassium-evoked neuronal release of serotonin in experimental chronic portal-systemic encephalopathy
14. Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: Implications for thymoleptic drug safety in liver insufficiency
15. Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy
16. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivate
17. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine
18. Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges
19. A racemic HPLC-method for routine TDM of the novel antidepressant venlafaxine and its main relevant metabolites in serum
20. 1B autoreceptor blocking properties of the beta adrenoceptor antagonist (-)penbutolol
21. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine
22. 14C]2-deoxy-D-glucose autoradiography
23. Basic characteristics of noradrenaline release in the hippocampus of intact and 6-hydroxydopamine-lesioned rats as studied by in vivo microdialysis
24. The portacaval and splenocaval shunt in the normal rat. A morphometric and functional reevaluation
25. Venlafaxine: A heterocyclic antidepressant
26. Venlafaxine: A review of its pharmacology and therapeutic potential in depression
27. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite
28. New antidepressants: Use in high-risk patients
29. Mirtazapine oral single dose kinetics in patients with different degrees of renal failure
30. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
31. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier